News Releases

23 Oct '23
Quince Therapeutics Completes Acquisition of EryDel S.p.A.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 23, 2023-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, announced the successful
PDF Version
06 Sep '23
Quince Therapeutics Appoints Dr. Charles S. Ryan as President
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 6, 2023-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced the appointment of Charles S.
PDF Version
24 Jul '23
Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity
Well-capitalized into 2026 with ability to fully fund lead asset EryDex expected through Phase 3 trial under special protocol assessment (SPA) and to NDA submission EryDex utilizes autologous intracellular drug encapsulation (AIDE) technology designed for slow release of steroids over several weeks
PDF Version
05 Apr '23
Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 5, 2023-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that its Board of Directors (the “Board”)
PDF Version
Displaying 1 - 10 of 11